Jild 5 Nomeri 1 (2026): Yanvar–Fevral
21-31
2026-02-27
Ochiq kirish

Surunkali obstruktiv o'pkalar kasalligi va konjestiv yurak yetishmovchiligi: IARC-ICPMS. Inson geni bo'yicha uchta klinik qo'llanma: komorbidlik, patofiziologiya, diagnostika va boshqaruv bo'yicha adabiyotlarni tahlil qilish

Abdigaffor G.Gadayev
Rustam I.Turakulov
Baxtiyor A.Nurullayev
DOI: https://doi.org/10.56121/MSU-2026-1-00003

Qabul qilingan: 2026-01-05 12:23:15

Nashr etilgan: 2026-02-27

PDF (inglizcha)
Crossmark Crossmark

Annotatsiya








Surunkali obstruktiv o'pkalar kasalligi (SOKK) va konjestiv yurak yetishmovchiligi (KYY) dunyodagi asosiy kasalliklar va o'lim sabablaridan biridir. Yuqori komorbidlik yuklamasi klinik diagnostika va davolash masalalarini murakkablashtiradi, chunki ular bir-biriga o'xshash simptomlar, umumiy xavf omillari va o'zaro bog'liq patofiziologik jarayonlarga ega. Ushbu narrativ sharh, ushbu bemorlar uchun epidemiologiya, patofiziologiya, diagnostika muammolari va terapevtik strategiyalar bo'yicha so'nggi dalillarni umumlashtiradi. Sharhlar PubMed, MEDLINE va EMBASE manbalarida 2016-2024 yillarda tizimli qidiruv orqali aniqlangan. Mavjud ma'lumotlar shuni ko'rsatadiki, SOKK KYY bilan bemorlarning 20-30% da uchraydi va o'xshash miqdorda o'rta darajadagi va og'ir SOKKda chap qorincha disfunktsiyasi mavjud. Kognitiv disfunktsiya yomon klinik natijalarni oldindan ko'rsatishning mustaqil belgisidir, shu jumladan yuqori kasalxonaga yotqizish va o'lim darajalarini. Tizimli yallig'lanish, oksidlovchi stress, skelet muskullarining disfunktsiyasi va neyrogormonal aktivatsiya - bu turli kasalliklarni bog'laydigan umumiy yo'llardir. Differential diagnostika klinik simptomlarning o'zaro bog'liqligi tufayli cheklangan; ammo, har bir keltirilgan biomarker umumiy diagnostik qiymatga ega: natriyuretik peptidlar chap yurak yetishmovchiligi tufayli o'pkada gipertenziya mavjudligini aniqlaydi, ehokardiografiya yurak kasalliklarining asosiy strukturasini baholashga yordam beradi va o'pkalar funksiyasini sinovdan o'tkazish asosiy patologiyani aniqlashga yordam beradi. Davolash shaxsiylashtirilgan va ko'p qirrali yondashuv bo'lishi kerak, bu beta-blokatorlar va bronxolitiklar bilan bog'liq dori xavfsizligiga, shuningdek, pulmonar va kardiyologik reabilitatsiya kabi nofarmakologik strategiyalarga e'tibor qaratadi. Ushbu sharh, birgalikda klinik baholash zarurligini ta'kidlaydi va ushbu yuqori xavf guruhini yanada ko'proq prospektiv tadqiqotlar o'tkazilishini qo'llab-quvvatlaydi.






 


Kalit so‘zlar

Adabiyotlar ro'yxati

  1. Adeloye D., Song P., Zhu Y., et al. (2022). Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respiratory Medicine, 10(5), 447–458. https://doi.org/10.1016/S2213-2600(21)00511-7.

  2. Agusti A., & Faner R. (2017). Systemic inflammation and comorbidities in chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society, 14(3), 219–226. https://doi.org/10.1513/AnnalsATS.201606-469AW}.

  3. Anker S. D., Butler J., Filippatos G., et al. (2021). Empagliflozin in heart failure with a preserved ejection fraction. New England Journal of Medicine, 385(16), 1451–1461. https://doi.org/10.1056/NEJMoa2107038.

  4. Müllerová H., Agusti A., Erqou S., & Mapel D. W. (2020). Cardiovascular comorbidity in COPD: systematic literature review. Chest, 141(5), 1233–1241. https://doi.org/10.1378/chest.11-0890.

  5. Barnes P. J. (2016). Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 138(1), 16–27. https://doi.org/10.1016/j.jaci.2016.05.011.

  6. Bhatt S. P., Dransfield M. T., Bhatt S. P., et al. (2021). Cardiovascular safety of indacaterol-glycopyrronium versus salmeterol-fluticasone in COPD: FLAME trial. American Journal of Respiratory and Critical Care Medicine, 204(5), 531–542. https://doi.org/10.1164/rccm.202006-2606OC.

  7. Mentz R. J., Kelly J. P., von Lueder T. G., et al. (2016). Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. Journal of the American College of Cardiology, 64(21), 2281–2293. https://doi.org/10.1016/j.jacc.2014.08.036.

  8. Vestbo J., Anderson J. A., Brook R. D., et al. (2016). Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet, 387(10030), 1817–1826. https://doi.org/10.1016/S0140-6736(16)30069-1.

  9. Schiattarella G. G., & Hill J. A. (2018). Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload. Circulation, 131(16), 1435–1447. https://doi.org/10.1161/CIRCULATIONAHA.115.013894.

  10. Chow S. L., Maisel A. S., Anand I., et al. (2017). Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation, 135(22), e1054–e1091. https://doi.org/10.1161/CIR.0000000000000490.

  11. Januzzi J. L., & Mann D. L. (2019). Natriuretic peptide measurement in heart failure: the good, the bad, and the future. JACC: Heart Failure, 7(4), 299–301. https://doi.org/10.1016/j.jchf.2019.01.007.

  12. Srivaratharajah K., Coutinho T., deKemp R., et al. (2016). Reduced myocardial flow in heart failure patients with preserved ejection fraction. Circulation: Heart Failure, 9(7), e002562. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002562.

  13. Agustí A., Celli B. R., Criner G. J., et al. (2023). Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. American Journal of Respiratory and Critical Care Medicine, 207(7), 819–837. https://doi.org/10.1164/rccm.202301-0106PP.

  14. Maltais F., Decramer M., Casaburi R., et al. (2014). An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 189(9), e15–e62. https://doi.org/10.1164/rccm.201402-0373ST.

  15. Groenewegen A., Rutten F. H., Mosterd A., & Hoes A. W. (2020). Epidemiology of heart failure. European Journal of Heart Failure, 22(8), 1342–1356. https://doi.org/10.1002/ejhf.1858.

  16. Guazzi M., Arena R., Halle M., Piepoli M. F., Myers J., & Lavie C. J. (2016). 2016 Focused Update: Clinical Recommendations for Cardiopulmonary Exercise Testing Data Assessment in Specific Patient Populations. Circulation, 133(24), e694–e711. https://doi.org/10.1161/CIR.0000000000000406.

  17. Rutten F. H., Cramer M. J., Lammers J. W., Grobbee D. E., & Hoes A. W. (2016). Heart failure and chronic obstructive pulmonary disease: an ignored combination? European Journal of Heart Failure, 8(7), 706–711. https://doi.org/10.1016/j.ejheart.2006.01.010.

  18. Lipworth B., Skinner D., Devereux G., et al. (2016). Underuse of beta-blockers in heart failure complicated by chronic obstructive pulmonary disease. Heart, 102(23), 1909–1914. https://doi.org/10.1136/heartjnl-2016-309458.

  19. Holland A. E., Mahal A., Hill C. J., et al. (2017). Home-based rehabilitation for COPD using minimal resources: A randomised controlled equivalence trial. Thorax, 72(1), 57–65. https://doi.org/10.1136/thoraxjnl-2016-208514.

  20. Tham Y. K., Bernardo B. C., Ooi J. Y. Y., Weeks K. L., & McMullen J. R. (2017). Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Archives of Toxicology, 89(9), 1401–1438. https://doi.org/10.1007/s00204-015-1477-x.

  21. GBD 2019 Diseases and Injuries Collaborators. (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, 396(10258), 1204–1222. https://doi.org/10.1016/S0140-6736(20)30925-9.

  22. Januzzi J. L., Prescott M. F., Butler J., et al. (2019). Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure. JAMA, 322(11), 1085–1095. https://doi.org/10.1001/jama.2019.12821.

  23. McMurray J. J. V., Solomon S. D., Inzucchi S. E., et al. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381(21), 1995–2008. https://doi.org/10.1056/NEJMoa1911303.

  24. Pellicori P., Kallvikbacka-Bennett A., Dierckx R., et al. (2017). Prognostic significance of changes in ejection fraction in patients with chronic heart failure. Heart, 104(9), 744–751. https://doi.org/10.1136/heartjnl-2017-311614.

  25. Piepoli M. F., Conraads V., Corrà U., et al. (2016). Exercise training in heart failure: From theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. European Journal of Heart Failure, 13(4), 347–357. https://doi.org/10.1093/eurjhf/hfr017.

  26. Ponikowski P., Voors A. A., Anker S. D., et al. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 37(27), 2129–2200. https://doi.org/10.1093/eurheartj/ehw128.

  27. Kirkham P. A., & Barnes P. J. (2016). Oxidative stress in COPD. Chest, 144(1), 266–273. https://doi.org/10.1378/chest.12-2664.

  28. Rutten F. H., Cramer M. J., Lammers J. W., Grobbee D. E., & Hoes A. W. (2016). Heart failure and chronic obstructive pulmonary disease: an ignored combination? European Journal of Heart Failure, 8(7), 706–711. https://doi.org/10.1016/j.ejheart.2006.01.010.

  29. Cazzola M., Rogliani P., Matera M. G., et al. (2019). Cardiovascular effects of bronchodilators: between myths and realities. Expert Opinion on Drug Safety, 18(11), 1017–1028. https://doi.org/10.1080/14740338.2019.1670149.

  30. Bhatt S. P., Wells J. M., Kinney G. L., et al. (2017). Beta-blockers are associated with a reduction in COPD exacerbations. Thorax, 71(1), 8–14. https://doi.org/10.1136/thoraxjnl-2015-207251.

  31. Celli B. R., Locantore N., Yates J., et al. (2019). Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 185(10), 1065–1072. https://doi.org/10.1164/rccm.201110-1792OC.

  32. Spruit M. A., Holland A. E., Singh S. J., Tonia T., Ward D. E., & Puhan M. A. (2020). COVID-19: interim guidance on rehabilitation in the hospital and post-hospital phase from a European Respiratory Society and American Thoracic Society-coordinated International Task Force. European Respiratory Journal, 56(6), 2002197. https://doi.org/10.1183/13993003.02197-202.

  33. Peoples J. N., Saraf A., Ghazal N., Pham T. T., & Kwong J. Q. (2019). Mitochondrial dysfunction and oxidative stress in heart disease. Experimental and Molecular Medicine, 51(12), 1–13. https://doi.org/10.1038/s12276-019-0355-7.

  34. Agustí A., Celli B. R., Criner G. J., et al. (2023). Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. American Journal of Respiratory and Critical Care Medicine, 207(7), 819–837. https://doi.org/10.1164/rccm.202301-0106PP.

  35. Bozbay M., Atalay M. K., Karabay C. Y., et al. (2018). Pulmonary hypertension in patients with chronic obstructive pulmonary disease: hemodynamic, echocardiographic, and clinical evaluation. Cardiology Journal, 25(4), 465–473. https://doi.org/10.5603/CJ.a2017.0147.

  36. World Health Organization. (2023). Chronic obstructive pulmonary disease (COPD) fact sheet. Retrieved from https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd).

Mualliflar haqida

Abdigaffor G.Gadayev
abgadaev@yahoo.com
Toshkent davlat tibbiyot universiteti
Rustam I.Turakulov
rustamturakulov571@gmail.com
Toshkent davlat tibbiyot universiteti.
Baxtiyor A.Nurullayev
bahtiyor.nurullayev93@gmail.com
Toshkent davlat tibbiyot universiteti

Litsenziya

Mualliflik huquqi (c) 2026 O`zbekiston tibbiyot ilmi

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Qanday iqtibos keltirish kerak

1.
Surunkali obstruktiv o’pkalar kasalligi va konjestiv yurak yetishmovchiligi: IARC-ICPMS. Inson geni bo’yicha uchta klinik qo’llanma: komorbidlik, patofiziologiya, diagnostika va boshqaruv bo’yicha adabiyotlarni tahlil qilish. MSU [Internet]. 2026 Feb. 27 [cited 2026 May 5];5(1):21-3. Available from: https://fdoctors.uz/index.php/journal/article/view/257
Crossref
Scopus
Google Scholar
Europe PMC

O'xshash maqolalar

Siz ham ushbu maqola uchun {$ advancedSearchLink} olishingiz mumkin.


ISSN 2181-3612 (Online)